(Q44513029)

3 December 2017

title

An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia (English)

1 reference

3 December 2017

0 references

1 reference

1

Timo Erkinjuntti

1 reference

3 December 2017

Alexander Kurz

2

1 reference

3 December 2017

Gary W Small

3

1 reference

3 December 2017

Roger Bullock

4

1 reference

3 December 2017

Sean Lilienfeld

5

1 reference

3 December 2017

C V Damaraju

6

1 reference

3 December 2017

GAL-INT-6 Study Group

7

1 reference

3 December 2017

publication date

1 June 2003

1 reference

3 December 2017

published in

Clinical Therapeutics

1 reference

3 December 2017

volume

25

1 reference

3 December 2017

issue

6

1 reference

3 December 2017

page(s)

1765-1782

1 reference

Prevalence and outcomes of vascular cognitive impairment

3 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980168-6

7 January 2021

Alzheimer disease and cerebrovascular pathology: an update

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980168-6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980168-6

7 January 2021

Vascular cognitive impairment and vascular dementia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980168-6

7 January 2021

The cholinergic hypothesis of geriatric memory dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980168-6

7 January 2021

Neurochemical profiles in cerebrospinal fluid of stroke-prone spontaneously hypertensive rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980168-6

7 January 2021

Pathogenesis of vascular dementia in stroke-prone spontaneously hypertensive rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980168-6

7 January 2021

Donepezil treatment of vascular dementia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980168-6

7 January 2021

An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980168-6

7 January 2021

Rivastigmine in subcortical vascular dementia: an open 22-month study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980168-6

7 January 2021

Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980168-6

7 January 2021

Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980168-6

7 January 2021

Galantamine is an allosterically potentiating ligand of the human alpha4/beta2 nAChR

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980168-6

7 January 2021

A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980168-6

7 January 2021

Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980168-6

7 January 2021

Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980168-6

7 January 2021

Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980168-6

7 January 2021

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980168-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980168-6

1 reference

7 January 2021

A new rating scale for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980168-6

7 January 2021

Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980168-6

7 January 2021

The Neuropsychiatric Inventory: assessing psychopathology in dementia patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980168-6

7 January 2021

The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980168-6

7 January 2021

A 12-month, randomized, placebo-controlled trial of propentofylline (HWA 285) in patients with dementia according to DSM III-R. The European Propentofylline Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980168-6

7 January 2021

Propentofylline in the treatment of Alzheimer's disease and vascular dementia: a review of phase III trials

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980168-6

7 January 2021

The disability assessment for dementia scale: a 12-month study of functional ability in mild to moderate severity Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980168-6

7 January 2021

10.1016/S0149-2918(03)80168-6

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/hufrcdyrazgnfftah7peepmgae

30 July 2022

mapped directly with Wikidata item

Fatcat ID

release_hufrcdyrazgnfftah7peepmgae

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/hufrcdyrazgnfftah7peepmgae

30 July 2022

mapped directly with Wikidata item

https://api.fatcat.wiki/v0/release/hufrcdyrazgnfftah7peepmgae

1 reference

30 July 2022